| Literature DB >> 34641854 |
Hanjing Kong1, Chao Fang1, Qiang Chu1,2, Zefeng Hu1, Yike Fu2, Gaorong Han1, Xiang Li3,4, Yi Zhou5.
Abstract
Nanoparticles, presenting catalytic activity to induce intracellular oxidative species, have been extensively explored for tumor treatment, but suffer daunting challenges in the limited intracellular H2O2 and thus suppressed therapeutic efficacy. Here in this study, a type of composite nanoparticles, consisting CaO2 core and Co-ferrocene shell, is designed and synthesized for combinational tumor treatment. The findings indicate that CaO2 core can be hydrolyzed to produce large amounts of H2O2 and calcium ions at the acidic tumor sites. Meanwhile, Co-ferrocene shell acts as an excellent Fenton catalyst, inducing considerable ROS generation following its reaction with H2O2. Excessive cellular oxidative stress triggers agitated calcium accumulation in addition to the calcium ions released from the particles. The combined effect of intracellular ROS and calcium overload causes significant tumor inhibition both in vitro and in vivo.Entities:
Keywords: CaO2@Co-ferrocene; Calcium overload; ROS generation; Self-supplied H2O2; Tumor inhibition
Mesh:
Substances:
Year: 2021 PMID: 34641854 PMCID: PMC8507391 DOI: 10.1186/s12951-021-01055-4
Source DB: PubMed Journal: J Nanobiotechnology ISSN: 1477-3155 Impact factor: 10.435
Fig. 1Schematic illustration for the functioning mechanism of CaO2@Co-Fc
Fig. 2a Schematic illustration of the synthesis procedure of CaO2@Co-Fc. b SEM image of CaO2. c SEM image of CaO2@Co-Fc. d TEM image of CaO2@Co-Fc. e XPS survey spectra of CaO2@Co-Fc. f Size distribution of CaO2and CaO2@Co-Fc. g Zeta potential of CaO2 and CaO2@Co-Fc
Fig. 3UV–vis spectra of CaO2@Co-Fc with varied concentrations in TMB solutions of (a) pH 5 and (b) pH 7. c H2O2 release profile of CaO2@Co-Fc at different pH values. d Time-course absorbance at 655 nm with different concentrations of CaO2@Co-Fc in TMB solution (e) EPR analysis of ·OH production of CaO2@Co-Fc at different pH values. f Schematic illustration of the in vitro performance of CaO2@Co-Fc
Fig. 4a The viability of 7702 and HUVEC cells incubated with CaO2@Co-Fc with varied concentrations. b Viability of 4T1 tumor cells treated with different concentrations of CaO2@Co-Fc. c Fluorescence images of calcein-AM and propidium iodide (PI) stained 4T1 cells treated with different concentrations of CaO2@Co-Fc. d Intracellular H2O2 content in 4T1 cells after being treated with CaO2@Co-Fc. Fluorescence images of (e) ROS level and (f) Ca2+ ions in 4T1 cells with different treatments. g The expression of PMCA4, TRPA1, BAX, BCl-2 and caspace-3 in 4T1 cells after treated with CaO2@Co-Fc. h Schematic illustration for the intracellular functioning mechanism of CaO2@Co-Fc
Fig. 5a Experimental procedures of injection treatment. b Body weight and c relative cancer volume variations of 4T1 tumor-bearing mice after different treatments within 14 days. d Weight and e representative photos of the tumors collected from different groups at 14th day. f H&E and g ki67 stained tumor slices collected from different groups at 14th day. (Group 1: PBS, Group 2: Co-Fc MOF, Group 3: 5 mg/kg CaO2@Co-Fc, Group 4: 15 mg/kg CaO2@Co-Fc.)